Weekly Briefing for September 28 to October 4, 2026

From Physician in the Loop: Pathology · 3:17

Show by Nomad Medical

A pooled analysis of 1,038 patients given neoadjuvant therapy for melanoma, published Oct. 1 in Nature Medicine, found five-year relapse-free survival of 92.7% after pathologic complete response to checkpoint inhibitors, versus 35.2% after nonresponse.A second Nature Medicine study reported 95% sensitivity at 90% specificity for a urine cell-free RNA assay in localized bladder cancer, and the Food and Drug Administration (FDA) listed final guidance on artificial intelligence-enabled device software among its fiscal 2027 priorities.Read this week's roundup and its sources: https://physicianintheloop.org/specialties/pathology/2026-09-28/The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

More episodes of Physician in the Loop: Pathology

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.